Artiva Biotherapeutics, Inc.ARTVNASDAQ
LOADING
|||
ARTV Revenue Growth (YoY Quarterly)•+0.00%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | -100.00% | -100.00% | +0.00% | +0.00% |
| Gross Profit Growth | -100.00% | -100.00% | -100.00% | +0.00% | +0.00% |
| EBITDA Growth | -255.78% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | -269.60% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -254.91% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -176.67% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -176.67% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +159.43% | +19.24% | +38.44% | +4.71% | +0.80% |
| Weighted Average Shares Diluted Growth | +159.43% | +19.24% | +38.44% | +4.71% | +0.80% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -91.70% | -100.00% | -97.95% | +25.39% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +0.00% | +99.38% | +112.13% | +123.14% | -34.01% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | -36.22% |
| Debt Growth | +0.00% | -15.13% | -13.91% | -16.12% | -21.89% |
| R&D Expense Growth | +3.51% | +19.40% | +52.85% | +44.82% | +25.49% |
| SG&A Expenses Growth | +73.06% | +56.30% | +42.71% | +28.31% | +9.42% |
1 / 2